Digital Content 
NEWS #PharmaBuzz
10 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/09/3251503/0/en/Ipsen-voluntarily-withdraws-Tazverik-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma.html
09 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/09/3251601/0/en/HUTCHMED-Announces-Update-on-Licensed-Oncology-Product-TAZVERIK-in-China.html
07 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/08/3201158/0/en/HUTCHMED-Announces-Expanded-Coverage-on-National-Reimbursement-Drug-List-and-Inclusion-in-the-First-Commercial-Insurance-Drug-List-in-China.html
21 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/21/3046949/0/en/HUTCHMED-Announces-NMPA-Conditional-Approval-for-TAZVERIK-tazemetostat-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-Lymphoma.html
03 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/04/2908483/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-for-Tazemetostat-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-Lymphoma-with-Priority-Review-Status.html
29 Sep 2023
// ONCLIVE
https://www.onclive.com/view/cd38-48-upregulation-with-tazemetostat-may-overcome-daratumumab-resistance-in-multiple-myeloma
Share